|Bid||4.0000 x 1000|
|Ask||4.0600 x 36200|
|Day's Range||3.7500 - 4.4000|
|52 Week Range||1.4000 - 6.0700|
|Beta (5Y Monthly)||0.52|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Amyris (NASDAQ: AMRS) gained over 12% today after the company announced it had signed a binding term sheet with the Infectious Disease Research Institute (IDRI) to collaborate on a SARS-CoV-2 vaccine candidate. Specifically, IDRI will develop a vaccine candidate based on its RNA vaccine platform, while Amyris will supply squalene for use in the vaccine adjuvant.
Investors need to pay close attention to Amyris (AMRS) stock based on the movements in the options market lately.
Q1 2020 Amyris Inc Earnings Call